FDA Approves Abrysvo to Treat Adults 18 to 59 Years of Age at Increased Risk of RSV.
The FDA has approved Abrysvo (Pfizer), a respiratory syncytial virus (RSV) vaccine for the prevention of lower respiratory tract infection
Read MoreThe FDA has approved Abrysvo (Pfizer), a respiratory syncytial virus (RSV) vaccine for the prevention of lower respiratory tract infection
Read MoreAGE | Updated: 23 October 2024 20:18 I am New Delhi [India]October 23 (ANI): Ayush Ministry will celebrate 9th Ayurveda
Read More